Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.
Jingyan YangKelly BlinzlerJoshua LankinSapna VijayakumarMartine C MaculaitisAhmed ShelbayaPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
US payers and physicians who have experience with biosimilars have favorable views of oncology biosimilars, particularly for treatment-naïve patients. A framework for integrating biosimilars into oncology practice is developing, primarily driven by insurance coverage, contracting, and cost benefits.